St. Jude Medical to acquire Thoratec for $3.4 billion in cash

St. Jude Medical agreed to acquire Thoratec for approximately $3.4 billion to expand its heart failure business. When the deal is finalized, Thoratec shareholders will receive $63.50 per share in cash, a 10 percent increase over Thoratec’s closing price the day before the announcement.

St. Jude said in a news release that Thoratec is a leader in the ventricular assist device market, which is estimated at around $750 million worldwide. Thoratec offers mechanical circulatory support technology to treat advanced heart failure. Its products include the HeartMate left ventricular assist device and the paracorporeal ventricular assist device. The company’s devices have been implanted in more than 20,000 patients.

The Heart Mate, a continuous flow device, is approved for bridge-to-transplantation and destination therapy and is the most widely-used left ventricular assist device in the U.S. The paracorporeal ventricular assist device is approved for bridge-to-transplantation and post-cardiotomy recovery from open heart surgery.

Thoratec also recently received conditional approval from the FDA to begin a trial testing a percutaneous heart pump (HeartMate PHP) for use in high-risk PCI procedures. The HeartMate PHP is already approved in Europe.

St. Jude’s heart failure portfolio includes a quadripolar cardiac resynchronization therapy, remote monitoring capabilities and CardioMEMS HF System. In 2014, the FDA approved the miniature CardioMEMS device to treat heart failure patients.

During the second quarter of 2015, St. Jude had approximately $20 million in CardioMEMS HF System sales, according to the company.

Per terms of the agreement, Thoratec can solicit other offers through Aug. 20. Thoratec must pay St. Jude $30 million if it finds a better offer by that time and $111 million if it finds a better offer after Aug. 20.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."